Peptide-Nucleic Acids TRIZ Cases

A fusion protein combining a signal, stalk, and anchor domain positions the target molecule away from the cell membrane to resolve steric hindrance.

Genetically encoded unnatural amino acid initiators enable site-specific polymer growth from recombinant proteins via atom transfer radical polymerization.

Segmented domains enable a cyclic peptide to form continuous networks that overcome toxic synthetic matrices while preventing biofilm accumulation.

Segmenting the mature TAFA-4 region eliminates complex ligation steps, reducing manufacturing costs while maintaining therapeutic activity.

NIP-V peptide disrupts N protein dimerization to inhibit viral replication, addressing the lack of effective small-molecule treatments.

Brush polymers incorporate therapeutic peptides as side chains to resist proteolytic digestion and improve cellular uptake.

Dynamic peptide probes overcome solubility and stability limits by switching conformations upon binding, improving detection reliability.

Fluorinated acetamide reporters overcome steric hindrance in bulky chemical labels by enabling efficient global profiling of molecular targets.

KDM2B-mediated epigenetic reprogramming accelerates neural differentiation, reducing treatment time and improving recovery rates for injured spinal nerves.

A split intein construct excises itself from splice products to enable high-throughput detection of specific gene events.

Transglutaminase mediates site-specific conjugation of growth factors to fibronectin, eliminating non-selective by-products and complex purification steps.

Hydrophilic linker systems transform solid phase peptide synthesis into a homogeneous liquid phase process, reducing solvent waste and improving product purity.

Single-chain Alphabody libraries enable high-affinity binder selection through defined sequence variation in helix surface and linker regions.

Peptide administration resolves chronic wound stagnation by triggering intracellular signaling cascades that drive re-epithelialization and angiogenesis.

A dipeptide comprising a non-proteogenic amino acid enables efficient coupling with polypeptides using phosphonium reagents in aqueous media.

A genetically encoded fusion protein uses fluorescence resonance energy transfer to detect intracellular ATP levels in living cells.

Hydrophilic beta-OP lactam linkers resolve the trade-off between structural stability and solubility in stapled helical peptides.

A novel peptide promotes myoblast proliferation and differentiation while inhibiting preadipocyte growth.

DNA aptamers replace antibodies to purify His-tagged proteins, resolving antibody availability limits while maintaining high specificity.

Knob-ELP fusion proteins target lacrimal gland acinar cells, overcoming anatomical barriers and enhancing bioavailability for ocular treatments.

Segmenting protein surfaces with orthogonal DNA patches resolves programming complexity in bottom-up assembly pathways.

An alpha-helical peptide disrupts tumor-derived vesicles to restore T-cell function.

Peptides combine cell membrane penetration with phosphorylation-blocking sequences to interrupt TDP-43 aggregation in neurodegenerative diseases.

Optimized acetonitrile gradients resolve glatiramer acetate from non-conforming copolymers to ensure pharmaceutical batch quality.

Peptidic activators target the PKG switch helix to modulate vasodilation without cGMP dependency.

Thioether crosslinks stabilize alpha helix peptides without increasing process complexity or requiring external chemical catalysts.

Replacing covalent bonds with reversible non-covalent interactions reduces photobleaching and extends imaging duration.

Iterative in situ click chemistry builds synthetic ligands that selectively inhibit the E17K Akt1 mutation without requiring a traditional binding pocket.

Peptides disrupt the Asf1-histone complex, sensitizing cancer cells while overcoming siRNA instability in vivo.

Bicyclic peptide ligands utilize sp3-rich molecular scaffolds to create constrained three-dimensional structures for specific protein targeting.

A peptide binds to the coronavirus N-protein to inhibit viral production.

Tetrameric docking peptides assemble polypeptide-based antibody drug conjugates with precise stoichiometry.

GH30 and GH5 xylanase polypeptides break down fiber bonds to release bound starch and gluten, reducing energy consumption in wet milling.

Helical bundle protein switches toggle bioactive peptide activity by balancing structural stability with conformational switching capability.

Incorporating serine and threonine allows autoclaving without degradation, resolving the contradiction between sterilization stability and structural integrity.

Modified amino acid sequences extend GIP receptor action duration, reducing gastrointestinal side effects while maintaining glycemic control.

A molecular scaffold supports peptide cyclization to generate multiple independent binding loops, resolving orthogonal ligation complexity.

Deleting the GPD1 gene in acid-resistant yeast reduces glycerol impurities, eliminating neutralization waste and improving lactide conversion yields.

A PAFRK29 polypeptide enters target cells via a cell-penetrating peptide sequence to inhibit the Smad2/3 signaling pathway.

Engineered Arabidopsis thaliana peptide achieves 100% cell penetration within one hour in serum environments, resolving low efficiency and stability issues.

A peptide sequence binds to the transcription factor CP2c to inhibit cancer cell growth.

Using low temperature induction and segmented chromatography to resolve assembly difficulties and improve purity of hydrophobic domain proteins.

Phosphorylated peptides induce organized apatite crystallization on collagen fibrils, overcoming the mechanical weakness of simple physical blends.

Substituting amino acids in the peptide linker decreases clipping rates, enabling stable liquid formulations of polypeptide constructs.

Circular tandem repeat proteins overcome natural sequence limitations by using geometric design to achieve high thermostability and solubility.

Segmenting the prion protein into specific epitopes induces targeted antibodies that neutralize PrPSc without triggering adverse immune reactions.

SAH1 polypeptide forms cyclic bonds via dehydration-condensation, reducing cytotoxicity while maintaining anti-Mycobacterium tuberculosis activity.